Article
Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jun 2021
Cleary James M, Wang Victoria, Heist Rebecca S, Kopetz E Scott, Mitchell Edith P, Zwiebel James A, Kapner Kevin S, Chen Helen X, Li Shuli, Gray Robert J, McShane Lisa M, Rubinstein Larry V, Patton David R, Meric-Bernstam Funda, Dillmon Melissa S, Williams P Mickey, Hamilton Stanley R, Conley Barbara A, Aguirre Andrew J, O'Dwyer Peter J, Harris Lyndsay N, Arteaga Carlos L, Chen Alice P, Flaherty Keith T
Abstract excerpt
PURPOSE: Preclinical and clinical data suggest that downstream inhibition with an MEK inhibitor, such as binimetinib, might be efficacious for NRAS-mutated cancers. PATIENTS AND METHODS: Patients enrolled in the NCI-MATCH trial master protocol underwent tumor biopsy and molecular profiling by targeted next-generation sequencing. Patients with NRAS-mutated tumors, except melanoma, were enrolled in subprotocol Z1A,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.